This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
SAR-COVID was a randomized phase 2 parallel-group trial evaluating subcutaneous sarilumab in hospitalised patients with moderate-severe COVID-19 infection.
| Feature | SAR-COVID |
|---|---|
| Condition | Covid-19 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | Maria del Rosario Garcia de Vicuña Pinedo |
2. Clinical Question
Population
Hospitalised patients with moderate-severe COVID-19 infection.
Intervention
Subcutaneous sarilumab.
Comparator
Standard of care.
Primary question
Does sarilumab improve clinical outcomes compared with standard of care?
3. Trial Design
Randomization
Patients were assigned using a randomized parallel-group design.
Masking
The registry reports no masking.
| Arm | Intervention |
|---|---|
| Arm 1 | Sarilumab (drug) |
| Arm 2 | Standard of care (other) |
4. Endpoints
| Endpoint | Time frame | Definition |
|---|---|---|
| Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation | 7 days from enrolment | Score ranges 1-7: 1. Death; 2. Hospitalized requiring invasive mechanical ventilation or ECMO; 3. Hospitalized requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized requiring supplemental oxygen; 5. Hospitalized not requiring supplemental oxygen requiring ongoing medical care; 6. Hospitalized not requiring supplemental oxygen no longer requiring ongoing medical care; 7. Not hospitalized. |
| Duration of hospitalisation (days) | 30 days from enrolment | Days from the date of enrolment to the date of discharge. |
| Death | 30 days from enrolment | Number of deaths. |
5. Planned Analysis
The registry lists the primary endpoints but does not report posted statistical analyses or trial results on ClinicalTrials.gov.
The clinical status ordinal scale endpoint is commonly analysed using methods appropriate for ordered categorical outcomes or changes over time, depending on the prespecified analysis plan. Duration of hospitalisation is a time-to-discharge measure and may be evaluated using methods that account for time until discharge. Death is a binary outcome over the defined follow-up period and is typically summarized using event counts and comparative measures between randomized groups.
6. Statistical Methodology
Randomization
Randomization creates comparable treatment groups in expectation and allows differences in outcomes to be interpreted as treatment comparisons rather than simple associations.
Ordinal clinical status outcomes
The 7-point ordinal scale captures increasing levels of clinical recovery and severity. Analysis of such endpoints must account for the ordered nature of the categories rather than treating them as unrelated groups.
Time-to-discharge outcomes
Duration of hospitalisation represents time from enrolment until discharge. Statistical approaches for these outcomes must consider patients who have not yet experienced discharge at the analysis time.
7. Statistical Methods Explained
Why use a 7-point ordinal scale?
An ordinal scale preserves clinically meaningful progression from death and intensive respiratory support requirements through recovery and discharge.
Why does randomization matter?
Randomization helps balance known and unknown prognostic factors between treatment groups, supporting unbiased treatment comparisons.
Why is duration of hospitalisation not simply a continuous outcome?
Hospitalisation duration is a time-to-event measure because discharge occurs at different times and some patients may remain hospitalized at assessment.
Why are results separated from planned analysis?
A statistical analysis requires both endpoint definitions and observed outcome data. The registry identifies planned measurements but does not report posted statistical analyses for SAR-COVID.
8. Limitations
- No posted statistical analyses: The ClinicalTrials.gov record does not report statistical estimates, confidence intervals, or p-values.
- Small randomized population: Enrollment was 30 patients, which affects precision of statistical estimates.
- Open-label design: The registry reports no masking, which can influence assessment of subjective outcomes.
- Ordinal endpoint interpretation: Clinical status scales require careful selection of statistical methods because categories are ordered.
9. Why This Trial Matters Statistically
| Concept | How it appears in SAR-COVID |
|---|---|
| Randomized design | Parallel randomized comparison of two treatment approaches. |
| Ordinal outcomes | Clinical status measured using a 7-point ordinal scale. |
| Time-to-event analysis | Duration of hospitalisation measured from enrolment to discharge. |
| Clinical endpoints | Mortality and clinical recovery outcomes evaluated over defined time frames. |
10. Related Tutorials
Learn more about the methods used in this trial:
No related tutorials are currently available.
11. Related Calculators
No related calculators are currently available.